JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences.
| Event: | Citi’s 2023 Annual BioPharma Conference |
| Format: | 1-on-1 meetings |
| Date: | September 6th, 2023 |
| Location: | Boston, MA |
| Event: | Emerging Growth Conference |
| Format: | Company presentation and 1-on-1 meetings |
| Date: | September 7th, 2023 |
| Time | 2:20 – 2:50 PM ET |
| Location: | Virtual |
| Event: | Cantor Fitzgerald Global Healthcare Conference |
| Format: | Fireside chat and 1-on-1 meetings |
| Date: | September 27th, 2023 |
| Time: | 3:35 – 4:05 PM ET |
| Location: | New York, NY |
Please reach out to your Citi and Cantor representatives to schedule, and register here to ensure you are able to attend the Emerging Growth conference and receive any updates that are released.
If attendees are not able to join the Emerging Growth Conference live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.
About Alpha Tau Medical, Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.10 |
| Daily Change: | 0.05 0.99 |
| Daily Volume: | 39,971 |
| Market Cap: | US$434.830M |
December 04, 2025 December 02, 2025 November 20, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
